Investors Warned of Large Losses in ImmunityBio Stock

Bernstein Liebhard LLP issues alert for shareholders who have suffered significant declines in IBRX shares.

Mar. 31, 2026 at 2:36pm

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up of various mechanical and electronic components that make up the inner workings of the financial industry, conveying a sense of the intricate systems that govern investments and stock trading.An extreme close-up of the complex financial infrastructure that underpins the stock market, highlighting the importance of transparency and accountability for investors.NYC Today

Bernstein Liebhard LLP, a prominent law firm, has announced that it is investigating potential securities fraud claims on behalf of investors who have experienced substantial losses in their holdings of ImmunityBio, Inc. (NASDAQ: IBRX) stock. The announcement comes as the biotech company's share price has plummeted, causing significant financial hardship for many shareholders.

Why it matters

This alert highlights the risks and potential legal issues facing investors in the volatile biotech sector, where rapid stock price movements can have severe financial consequences, especially for those who have invested heavily. The investigation by Bernstein Liebhard could lead to a class-action lawsuit, providing a path for affected shareholders to seek compensation for their losses.

The details

According to the announcement, Bernstein Liebhard is investigating whether ImmunityBio and its executives made false or misleading statements or failed to disclose material information about the company's business, operations, and prospects. This could have artificially inflated the stock price, leading to significant losses for investors who purchased shares at inflated prices.

  • The announcement was made on March 31, 2026.

The players

Bernstein Liebhard LLP

A prominent law firm that specializes in securities litigation and has announced an investigation into potential fraud claims related to ImmunityBio, Inc.

ImmunityBio, Inc.

A biotechnology company whose stock price has experienced significant declines, leading to substantial losses for many of its investors.

Got photos? Submit your photos here. ›

What’s next

Bernstein Liebhard LLP is currently investigating the potential claims and will determine whether to file a class-action lawsuit on behalf of affected ImmunityBio shareholders.

The takeaway

This alert serves as a warning to investors in the volatile biotech sector, highlighting the importance of conducting thorough research and being cautious when investing in high-risk stocks. The potential legal action by Bernstein Liebhard could provide a path for affected shareholders to seek compensation for their losses.